相似文献
1
Thromboangiitis Obliterans: 110 Years Old and Little Progress Made.
J Am Heart Assoc. 2018 Dec 4;7(23):e011214. doi: 10.1161/JAHA.118.011214.
2
Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease).
Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD012794. doi: 10.1002/14651858.CD012794.pub2.
3
Thromboangiitis obliterans (Buerger's disease) in a saphenous vein arterial graft.
Hum Pathol. 1987 Apr;18(4):402-4. doi: 10.1016/s0046-8177(87)80174-0.
4
Buerger's disease (thromboangiitis obliterans): an analysis of the arteriograms of 119 cases.
Clin Radiol. 1982 Mar;33(2):235-40. doi: 10.1016/s0009-9260(82)80068-8.
5
[Thromboangiitis obliterans (Buerger's disease) in 2 women].
Ned Tijdschr Geneeskd. 1996 Aug 31;140(35):1770-2.
6
Thromboangiitis obliterans (Buerger's disease).
Curr Opin Rheumatol. 2006 Jan;18(1):18-24. doi: 10.1097/01.bor.0000198000.58073.aa.
7
Thromboangiitis obliterans: an old disease in need of a new look.
Int J Cardiol. 2000 Aug 31;75 Suppl 1:S167-70; discussion S171-3. doi: 10.1016/s0167-5273(00)00185-6.
8
[Buerger's disease or thromboangiitis obliterans revealed by an enteric ischemia. Case report and literature review].
Gastroenterol Clin Biol. 2002 Apr;26(4):409-11.
9
Thromboangiitis obliterans (Buerger's disease) in women.
Medicine (Baltimore). 1987 Jan;66(1):65-72. doi: 10.1097/00005792-198701000-00002.
10
Buerger's disease in two brothers: iliac artery occlusion by thromboangiitis obliterans--case reports.
Angiology. 1998 May;49(5):409-14. doi: 10.1177/000331979804900511.
引用本文的文献
1
Exploring the oxidative and inflammatory markers landscape in Buerger's disease: A comparative analysis.
J Educ Health Promot. 2025 Jul 4;14:242. doi: 10.4103/jehp.jehp_146_24. eCollection 2025.
2
Acute myocardial infarction and left ventricular thrombus in a young male with thromboangiitis obliterans: a case report and literature review.
J Cardiothorac Surg. 2025 May 17;20(1):231. doi: 10.1186/s13019-025-03383-0.
3
Leprosy Mimicking Thrombangiitis Obliterans (Buerger's Disease): A Case Study.
Cureus. 2025 Mar 19;17(3):e80822. doi: 10.7759/cureus.80822. eCollection 2025 Mar.
4
Long-term outcomes and prognostic factors of major amputation in thromboangiitis obliterans after drug therapy and endovascular procedures: A real-world cohort study.
Sci Prog. 2025 Jan-Mar;108(1):368504251320766. doi: 10.1177/00368504251320766.
5
The Buerger's rabbit model: a closer step to unravelling thromboangiitis obliterans?
Thromb J. 2024 Jul 29;22(1):69. doi: 10.1186/s12959-024-00638-z.
6
Exploring Causal Relationships between Circulating Inflammatory Proteins and Thromboangiitis Obliterans: A Mendelian Randomization Study.
Thromb Haemost. 2024 Nov;124(11):1075-1083. doi: 10.1055/s-0044-1786809. Epub 2024 May 24.
7
Cannabis arteritis presenting with Raynaud's and digital ulcerations: a case-based review of a controversial thromboangiitis obliterans-like condition.
Clin Rheumatol. 2023 Jul;42(7):1981-1985. doi: 10.1007/s10067-023-06603-x. Epub 2023 Apr 25.
8
Protective Effects and Potential Mechanism of Tongxinluo on Mice with Thromboangiitis Obliterans Induced by Sodium Laurate.
Chin J Integr Med. 2023 Jul;29(7):608-616. doi: 10.1007/s11655-023-3630-3. Epub 2023 Mar 24.
9
Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways.
Front Pharmacol. 2022 Oct 11;13:1018438. doi: 10.3389/fphar.2022.1018438. eCollection 2022.
10
Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia.
Front Cardiovasc Med. 2021 Dec 6;8:769472. doi: 10.3389/fcvm.2021.769472. eCollection 2021.
本文引用的文献
1
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.
J Am Heart Assoc. 2018 Dec 4;7(23):e010677. doi: 10.1161/JAHA.118.010677.
2
How to Treat a Patient with Thromboangiitis Obliterans: A Systematic Review.
Ann Vasc Surg. 2018 May;49:219-228. doi: 10.1016/j.avsg.2017.10.022. Epub 2018 Feb 5.
3
Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease.
J Vasc Surg. 2018 Jun;67(6):1769-1777. doi: 10.1016/j.jvs.2017.09.020. Epub 2017 Nov 20.
4
Outcomes of endovascular recanalization versus autogenous venous bypass for thromboangiitis obliterans patients with critical limb ischemia due to tibioperoneal arterial occlusion.
J Vasc Surg. 2017 Oct;66(4):1133-1142.e1. doi: 10.1016/j.jvs.2017.03.425. Epub 2017 Jul 8.
5
Pharmacological treatment for Buerger's disease.
Cochrane Database Syst Rev. 2016 Feb 1;2:CD011033. doi: 10.1002/14651858.CD011033.pub2.
6
Cannabis-associated arterial disease.
Ann Vasc Surg. 2013 Oct;27(7):996-1005. doi: 10.1016/j.avsg.2013.01.002. Epub 2013 Jul 10.
7
Thromboangiitis obliterans.
Circulation. 2010 Apr 27;121(16):1858-61. doi: 10.1161/CIRCULATIONAHA.110.942383.
8
Thromboangiitis obliterans (Buerger's disease).
Curr Opin Rheumatol. 2006 Jan;18(1):18-24. doi: 10.1097/01.bor.0000198000.58073.aa.
9
Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease).
J Am Coll Cardiol. 2004 Dec 21;44(12):2410-1. doi: 10.1016/j.jacc.2004.09.029.
10
Clinical and social consequences of Buerger disease.
J Vasc Surg. 2004 Jan;39(1):176-80. doi: 10.1016/j.jvs.2003.08.006.
Zotero 插件